Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Ford stopped production of F-150 Lightning

2/15/23 F

Livent reported for 2022

2/15/23 LTHM

Goldman Sachs sold a stake in Cian to top management

2/15/23 CNRU

Airbnb ended 2022 with a profit

2/15/23 ABNB

Otkritie Bank sold 13.7% of Qiwi

2/14/23 QIWI

VSMPO-Avisma and Boeing joint venture suspended operations

2/14/23 VSMO

The Mastercard announced a quarterly dividend

2/14/23 MA

Coca-Cola reported for 2022

2/14/23 KO

Bank Trust in 2023 may sell part of Russneft prefs

2/14/23 RNFT

UAC will study the possibility of SSJ100 production in India

2/14/23 UNAC